Following on from information received from the company (Ipsen) who manufacture cabozantinib, NICE will be conducting an appraisal of [ID6184] Cabozantinib with nivolumab for untreated advanced renal cell carcinoma.
This was originally Terminated guidance TA785 - Nivolumab with cabozantinib for untreated advanced renal cell carcinoma.
https://www.nice.org.uk/guidance/ta785
The appraisal is anticipated to begin during early January 2023. A draft scope consultation is anticipated to be held during November 2022.